Wedbush raised the firm’s price target on Arvinas to $33 from $24 and keeps an Outperform rating on the shares. The firm notes the company shared full data from the Phase 1/2 trial of PROTAC ER degrader vepdegestrant plus CDK4/6i palbociclib at SABCS, demonstrating an impressive 11.1 mPFS in heavily pretreated ER+/HER2- metastatic breast cancer patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
- Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
- Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
- Arvinas, Pfizer announce updated Vepdegestrant data to be presented at SABCS
- Arvinas Announces Oversubscribed $350 Million Private Placement